Finemedix파인메딕스

Finemedix is loss-making on a trailing basis, though its shares have risen over three months and it has a recent overseas supply deal.

Finemedix makes endoscopic instruments and sold about ₩11.4B of revenue over the twelve months to H1 2026, with an operating loss of about ₩1.2B. Revenue fell 4.4% in 2025 and the operating loss widened sharply that year, while the balance sheet shows ₩4.1B of cash against ₩1.9B of borrowings. The share price closed at ₩5,860 on 2026-10-28, down 29% over one year but up 44.7% over three months.

What stands out

• Trailing operating margin is -10.2% and net margin is -5.2%, against -27.1% operating margin for 2025, so losses narrowed on the trailing view versus last year.
• Trailing free cash flow is positive at about ₩694M, even though the company reports operating and net losses.
• Valuation is shown as 1.7x book value and 2.9x sales, with no earnings-based multiples because earnings are negative.
• Peers in the data include TSE, Kctech, Classys, Park Systems and DI, several of which trade at higher price-to-earnings and price-to-book multiples than Finemedix's book multiple.
• Recent filings include a buyback trust contract signed in July 2026 and a status report on acquisition under a trust agreement dated 2026-10-26, and news reports a 3-year ODM contract with UK firm Crayo Medical (also reported as Crea Medical).

What to watch

• Next quarterly and half-year results, to see whether the operating loss keeps narrowing from the trailing figures.
• Progress of the buyback trust and the status reports on share acquisition filed under it.
• Foreign ownership has fallen from 1.6% to 1.1% over 60 days, and the data gives no reason for this; retail investors were net sellers over the last 20 days.